Ruxolitinib discontinuation in polycythemia vera:

[Manouche]

« After discontinuation, only 4 patients (18 %) received subsequent cytoreductive therapy, including hydroxyurea in one patient and pegylated interferon α-2a in three patients »… « discontinuation of ruxolitinib in PV was associated with generally favorable outcomes. However, there is a lack of available salvage therapies, highlighting the need for further therapeutic development in PV. »

pubmed.ncbi.nlm.nih.gov/340...

[Bluetop]

So is this suggesting that there was lasting benefit of taking ruxolitinib? 22 out of 93 discontinuing ruxilitinib seems quite a high proportion. Interesting. Thanks for posting.